ABBV-8E 12 -- a new Alzheimer’s treatment still in development -- received a fast-track designation from the U.S. Food and Drug Administration to be moved to clinical trials.
“We see potential in ABBV-8E 12 and the tau-focused approaches to progressive neurodegenrative diseases, such as early Alzheimer’s diseases and progressive supranuclear palsy (PSP),” Eric Karran, vice president of the Foundational Neuroscience Center, said.
“The initiation of clinical trial programs and the FDA’s fast-track designation for PSP signify important steps forward in ABBV’s ongoing commitment to investigating innovative scientific approaches with the hope of bringing new treatment options to patients.”
A fast-track designation allows a company to expedite the review of a new drug, and is often granted in cases where no satisfactory treatments are readily available.
FDA gives new Alzheimer's treatment fast-track designation
Alerts Sign-up